PMID- 33562741
OWN - NLM
STAT- MEDLINE
DCOM- 20211102
LR  - 20211102
IS  - 2073-4409 (Electronic)
IS  - 2073-4409 (Linking)
VI  - 10
IP  - 2
DP  - 2021 Feb 5
TI  - Tumor Evolution and Therapeutic Choice Seen through a Prism of Circulating Tumor 
      Cell Genomic Instability.
LID - 10.3390/cells10020337 [doi]
LID - 337
AB  - Circulating tumor cells (CTCs) provide an accessible tool for investigating tumor 
      heterogeneity and cell populations with metastatic potential. Although an 
      in-depth molecular investigation is limited by the extremely low CTC count in 
      circulation, significant progress has been made recently in single-cell 
      analytical processes. Indeed, CTC monitoring through molecular and functional 
      characterization may provide an understanding of genomic instability (GI) 
      molecular mechanisms, which contribute to tumor evolution and emergence of 
      resistant clones. In this review, we discuss the sources and consequences of GI 
      seen through single-cell analysis of CTCs in different types of tumors. We 
      present a detailed overview of chromosomal instability (CIN) in CTCs assessed by 
      fluorescence in situ hybridization (FISH), and we reveal utility of CTC 
      single-cell sequencing in identifying copy number alterations (CNA) oncogenic 
      drivers. We highlight the role of CIN in CTC-driven metastatic progression and 
      acquired resistance, and we comment on the technical obstacles and challenges 
      encountered during single CTC analysis. We focus on the DNA damage response and 
      depict DNA-repair-related dynamic biomarkers reported to date in CTCs and their 
      role in predicting response to genotoxic treatment. In summary, the suggested 
      relationship between genomic aberrations in CTCs and prognosis strongly supports 
      the potential utility of GI monitoring in CTCs in clinical risk assessment and 
      therapeutic choice.
FAU - Tayoun, Tala
AU  - Tayoun T
AD  - Gustave Roussy, Universite Paris-Saclay, "Circulating Tumor Cells" Translational 
      Platform, CNRS UMS3655-INSERM US23AMMICA, F-94805 Villejuif, France.
AD  - Gustave Roussy, INSERM, U981 "Molecular Predictors and New Targets in Oncology", 
      F-94805 Villejuif, France.
AD  - Faculty of Medicine, Universite Paris-Saclay, F-94270 Le Kremlin-Bicetre, France.
FAU - Oulhen, Marianne
AU  - Oulhen M
AD  - Gustave Roussy, Universite Paris-Saclay, "Circulating Tumor Cells" Translational 
      Platform, CNRS UMS3655-INSERM US23AMMICA, F-94805 Villejuif, France.
AD  - Gustave Roussy, INSERM, U981 "Molecular Predictors and New Targets in Oncology", 
      F-94805 Villejuif, France.
FAU - Aberlenc, Agathe
AU  - Aberlenc A
AD  - Gustave Roussy, Universite Paris-Saclay, "Circulating Tumor Cells" Translational 
      Platform, CNRS UMS3655-INSERM US23AMMICA, F-94805 Villejuif, France.
AD  - Gustave Roussy, INSERM, U981 "Molecular Predictors and New Targets in Oncology", 
      F-94805 Villejuif, France.
FAU - Farace, Francoise
AU  - Farace F
AD  - Gustave Roussy, Universite Paris-Saclay, "Circulating Tumor Cells" Translational 
      Platform, CNRS UMS3655-INSERM US23AMMICA, F-94805 Villejuif, France.
AD  - Gustave Roussy, INSERM, U981 "Molecular Predictors and New Targets in Oncology", 
      F-94805 Villejuif, France.
FAU - Pawlikowska, Patrycja
AU  - Pawlikowska P
AD  - Gustave Roussy, INSERM, U981 "Molecular Predictors and New Targets in Oncology", 
      F-94805 Villejuif, France.
LA  - eng
GR  - NA/Ligue Contre le Cancer/
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20210205
PL  - Switzerland
TA  - Cells
JT  - Cells
JID - 101600052
SB  - IM
MH  - Chromosomal Instability/*genetics
MH  - DNA Copy Number Variations/*genetics
MH  - DNA Damage/*genetics
MH  - DNA Repair/*genetics
MH  - Genomic Instability/*genetics
MH  - Genomics/*methods
MH  - Humans
MH  - Prognosis
PMC - PMC7915006
OTO - NOTNLM
OT  - DNA-repair
OT  - chromosomal instability
OT  - circulating tumor cells
OT  - genomic instability
OT  - tumor genetic heterogeneity
COIS- The authors declare no conflict of interest.
EDAT- 2021/02/11 06:00
MHDA- 2021/11/03 06:00
PMCR- 2021/02/05
CRDT- 2021/02/10 01:02
PHST- 2021/01/13 00:00 [received]
PHST- 2021/01/29 00:00 [revised]
PHST- 2021/02/02 00:00 [accepted]
PHST- 2021/02/10 01:02 [entrez]
PHST- 2021/02/11 06:00 [pubmed]
PHST- 2021/11/03 06:00 [medline]
PHST- 2021/02/05 00:00 [pmc-release]
AID - cells10020337 [pii]
AID - cells-10-00337 [pii]
AID - 10.3390/cells10020337 [doi]
PST - epublish
SO  - Cells. 2021 Feb 5;10(2):337. doi: 10.3390/cells10020337.